Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.78)
# 569
Out of 4,595 analysts
388
Total ratings
48.1%
Success rate
20.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $227 | $139.04 | +63.26% | 21 | Jul 20, 2026 | |
| GUTS Fractyl Health | Maintained: Buy | $8 | $0.685 | +1,067.88% | 17 | Jul 15, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $151 | $99.25 | +52.14% | 30 | Jul 7, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Hold | $436 | $477.10 | -8.61% | 38 | Jul 6, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | $429 | $205.52 | +108.74% | 35 | Jun 29, 2026 | |
| NGNE Neurogene | Maintained: Buy | $180 | $32.89 | +447.28% | 5 | Jun 29, 2026 | |
| PHAR Pharming Group | Maintained: Buy | $37 | $10.08 | +267.06% | 3 | Jun 22, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | $49 | $10.68 | +358.80% | 22 | Jun 16, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $79 | $24.91 | +217.14% | 23 | Jun 10, 2026 | |
| BBIO BridgeBio Pharma | Initiated Coverage: Buy | $104 | $80.09 | +29.85% | 1 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $11 | $1.23 | +794.31% | 5 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $116 → $111 | $60.02 | +84.94% | 20 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $75 | $25.52 | +193.89% | 5 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $43 | $5.51 | +680.40% | 15 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.7403 | +575.40% | 24 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $5.76 | +264.58% | 28 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.11 | +221.54% | 22 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 | $5.86 | +190.10% | 25 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 | $4.47 | +414.54% | 15 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 → $114 | $341.12 | n/a | 5 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $14.86 | n/a | 2 | Sep 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $130.21 | n/a | 4 | Jan 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $119.52 | n/a | 1 | Jan 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $43.63 | n/a | 4 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $27 | $105.95 | n/a | 2 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 | $0.0732 | n/a | 5 | Nov 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $2.58 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $47.99 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $28.03 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $16 | $1.92 | n/a | 5 | May 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.88 | n/a | 2 | Jan 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.91 | n/a | 1 | May 13, 2014 |
Palvella Therapeutics
Jul 20, 2026
Reiterated: Buy
Price Target: $227
Current: $139.04
Upside: +63.26%
Fractyl Health
Jul 15, 2026
Maintained: Buy
Price Target: $8
Current: $0.685
Upside: +1,067.88%
Rhythm Pharmaceuticals
Jul 7, 2026
Maintained: Buy
Price Target: $151
Current: $99.25
Upside: +52.14%
Vertex Pharmaceuticals
Jul 6, 2026
Maintained: Hold
Price Target: $436
Current: $477.10
Upside: -8.61%
Alnylam Pharmaceuticals
Jun 29, 2026
Maintained: Buy
Price Target: $429
Current: $205.52
Upside: +108.74%
Neurogene
Jun 29, 2026
Maintained: Buy
Price Target: $180
Current: $32.89
Upside: +447.28%
Pharming Group
Jun 22, 2026
Maintained: Buy
Price Target: $37
Current: $10.08
Upside: +267.06%
Intellia Therapeutics
Jun 16, 2026
Maintained: Buy
Price Target: $49
Current: $10.68
Upside: +358.80%
Ultragenyx Pharmaceutical
Jun 10, 2026
Maintained: Buy
Price Target: $79
Current: $24.91
Upside: +217.14%
BridgeBio Pharma
Jun 3, 2026
Initiated Coverage: Buy
Price Target: $104
Current: $80.09
Upside: +29.85%
May 27, 2026
Maintained: Buy
Price Target: $12 → $11
Current: $1.23
Upside: +794.31%
May 22, 2026
Maintained: Buy
Price Target: $116 → $111
Current: $60.02
Upside: +84.94%
May 21, 2026
Maintained: Buy
Price Target: $75
Current: $25.52
Upside: +193.89%
May 19, 2026
Maintained: Buy
Price Target: $43
Current: $5.51
Upside: +680.40%
May 18, 2026
Maintained: Buy
Price Target: $5
Current: $0.7403
Upside: +575.40%
May 8, 2026
Maintained: Buy
Price Target: $21
Current: $5.76
Upside: +264.58%
May 7, 2026
Maintained: Buy
Price Target: $10
Current: $3.11
Upside: +221.54%
May 6, 2026
Maintained: Buy
Price Target: $17
Current: $5.86
Upside: +190.10%
Apr 21, 2026
Maintained: Buy
Price Target: $23
Current: $4.47
Upside: +414.54%
Feb 28, 2022
Maintained: Buy
Price Target: $83 → $114
Current: $341.12
Upside: n/a
Sep 15, 2021
Upgraded: Buy
Price Target: n/a
Current: $14.86
Upside: n/a
Jan 4, 2021
Upgraded: Buy
Price Target: n/a
Current: $130.21
Upside: n/a
Jan 4, 2021
Upgraded: Buy
Price Target: n/a
Current: $119.52
Upside: n/a
Jun 25, 2020
Maintained: Hold
Price Target: n/a
Current: $43.63
Upside: n/a
Dec 16, 2019
Maintained: Buy
Price Target: $18 → $27
Current: $105.95
Upside: n/a
Nov 9, 2018
Downgraded: Hold
Price Target: $18
Current: $0.0732
Upside: n/a
Oct 9, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $2.58
Upside: n/a
Oct 9, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $47.99
Upside: n/a
Oct 9, 2018
Initiated Coverage: Buy
Price Target: $35
Current: $28.03
Upside: n/a
May 4, 2017
Reiterated: Buy
Price Target: $19 → $16
Current: $1.92
Upside: n/a
Jan 11, 2017
Maintained: Hold
Price Target: n/a
Current: $1.88
Upside: n/a
May 13, 2014
Maintained: Hold
Price Target: n/a
Current: $3.91
Upside: n/a